MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
Provided By GlobeNewswire
Last update: Feb 26, 2025
ZUG, Switzerland, February 26, 2025 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases, today announced its financial results for the fourth quarter and year ended December 31, 2024.
Read more at globenewswire.com
